A new prognostic model for cancer-specific survival after radical cystectomy including pretreatment thrombocytosis and standard pathological risk factors

BJU International

Volumn 110, Issue 11 B, 2012, Pages

  Todenhöfer, Tilman ^a   Renninger, Markus ^a   Schwentner, Christian ^a   Stenzl, Arnulf ^a   Gakis, Georgios ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Bladder cancer; Platelets; Radical cystectomy; Risk factor; Thrombocytosis

Indexed keywords

ACCURACY; ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CONTROLLED STUDY; CYSTECTOMY; CYSTOSCOPY; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INTRAVENOUS PYELOGRAPHY; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SCORING SYSTEM; THROMBOCYTE COUNT; THROMBOCYTOSIS; TUMOR INVASION; BLADDER TUMOR; BLOOD; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; FOLLOW UP; GERMANY; METHODOLOGY; MIDDLE AGED; MORTALITY; PREOPERATIVE PERIOD; PROGNOSIS; RISK ASSESSMENT; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; CYSTECTOMY; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GERMANY; HUMANS; MALE; MIDDLE AGED; PLATELET COUNT; PREOPERATIVE PERIOD; PROGNOSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SURVIVAL RATE; THROMBOCYTOSIS; URINARY BLADDER NEOPLASMS;

MLCS; MLOWN;

EID: 84876422037     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2012.11231.x     Document Type: Article

References (37)

1. Stein JP, Lieskovsky G, Cote R et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001; 19: 666-75
2. Hautmann RE, Volkmer BG, Schumacher MC, Gschwend JE, Studer UE. Long-term results of standard procedures in urology: the ileal neobladder. World J Urol 2006; 24: 305-14
3. Shariat SF, Youssef RF, Gupta A et al. Association of angiogenesis related markers with bladder cancer outcomes and other molecular markers. J Urol 2010; 183: 1744-50
4. Gakis G, Todenhofer T, Stenzl A. The prognostic value of hematological and systemic inflammatory disorders in invasive bladder cancer. Curr Opin Urol 2011; 21: 428-33
5. Pedersen LM, Milman N. Diagnostic significance of platelet count and other blood analyses in patients with lung cancer. Oncol Rep 2003; 10: 213-6
6. Brockmann MA, Giese A, Mueller K et al. Preoperative thrombocytosis predicts poor survival in patients with glioblastoma. N euro Oncol 2007; 9: 335-42
7. Inoue K, Kohashikawa K, Suzuki S, Shimada M, Yoshida H. Prognostic significance of thrombocytosis in renal cell carcinoma patients. Int J Urol 2004; 11: 364-7
8. Qiu MZ, Yuan ZY, Luo HY et al. Impact of pretreatment hematologic profile on survival of colorectal cancer patients. Tumour Biol 2010; 31: 255-60
9. Sobin DH, Wiltehind C. TNM Classification of Malignant Tumours. New York, USA: Wiley-Liss, 2002
10. Margulis V, Lotan Y, Montorsi F, Shariat SF. Predicting survival after radical cystectomy for bladder cancer. BJU Int 2008; 102: 15-22
11. Iimura Y, Saito K, Fujii Y et al. Development and external validation of a new outcome prediction model for patients with clear cell renal cell carcinoma treated with nephrectomy based on preoperative serum C-reactive protein and TNM classification: the TNM-C score. J Urol 2009; 181: 1004-12
12. Harrell FE Jr, Califf RM, Pryor DB, Lee KL, Rosati RA. Evaluating the yield of medical tests. JAMA 1982; 247: 2543-6
13. Matuszewska M, Kuczynska-Wisnik D, Laskowska E, Liberek K. The small heat shock protein IbpA of Escherichia coli cooperates with IbpB in stabilization of thermally aggregated proteins in a disaggregation competent state. J Biol Chem 2005; 280: 12292-8
14. Symbas NP, Townsend MF, El-Galley R, Keane TE, Graham SD, Petros JA. Poor prognosis associated with thrombocytosis in patients with renal cell carcinoma. BJU Int 2000; 86: 203-7
15. Erdemir F, Kilciler M, Bedir S, Ozgok Y, Coban H, Erten K. Clinical significance of platelet count in patients with renal cell carcinoma. Urol Int 2007; 79: 111-6
16. Rogers CG, Palapattu GS, Shariat SF et al. Clinical outcomes following radical cystectomy for primary nontransitional cell carcinoma of the bladder compared to transitional cell carcinoma of the bladder. J Urol 2006; 175: 2048-53
17. Choong NW, Quevedo JF, Kaur JS. Small cell carcinoma of the urinary bladder. The Mayo Clinic experience. Cancer 2005; 103: 1172-8
18. Turalic H, Deamant FD, Reese JH. Paraneoplastic production of granulocyte colony-stimulating factor in a bladder carcinoma. Scand J Urol Nephrol 2006; 40: 429-32
19. Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol 1996; 49: 1373-9
20. Gakis G, Schwentner C, Todenhoefer T, Stenzl A. Current status of molecular markers for prognostication and outcome in invasive bladder cancer. BJU Int 2012; doi:10.1111/j.1464-410X.2011.10839.x
21. Chen MH, Chang PM, Chen PM et al. Prognostic significance of a pretreatment hematologic profile in patients with head and neck cancer. J Cancer Res Clin Oncol 2009; 135: 1783-90
22. Novara G, Svatek RS, Karakiewicz PI et al. Soft tissue surgical margin status is a powerful predictor of outcomes after radical cystectomy: a multicenter study of more than 4,400 patients. J Urol 2010; 183: 2165-70
23. Nakazaki H. Preoperative and postoperative cytokines in patients with cancer. Cancer 1992; 70: 709-13
24. Kabir S, Daar GA. Serum levels of interleukin-1, interleukin-6 and tumour necrosis factor-alpha in patients with gastric carcinoma. Cancer Lett 1995; 95: 207-12
25. Nakano T, Chahinian AP, Shinjo M et al. Interleukin 6 and its relationship to clinical parameters in patients with malignant pleural mesothelioma. Br J Cancer 1998; 77: 907-12
26. Caine GJ, Lip GY, Blann AD. Platelet-derived VEGF, Flt-1, angiopoietin-1 and P-selectin in breast and prostate cancer: further evidence for a role of platelets in tumour angiogenesis. Ann Med 2004; 36: 273-7
27. Boucharaba A, Serre CM, Gres S et al. Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer. J Clin Invest 2004; 114: 1714-25
28. Nieswandt B, Hafner M, Echtenacher B, Mannel DN. Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res 1999; 59: 1295-300
29. Karpatkin S, Pearlstein E. Role of platelets in tumor cell metastases. Ann Intern Med 1981; 95: 636-41
30. Buck I, Morceau F, Grigorakaki C, Dicato M, Diederich M. Linking anemia to inflammation and cancer: the crucial role of TNFalpha. Biochem Pharmacol 2009; 77: 1572-9
31. Alexandrakis MG, Passam FH, Moschandrea IA et al. Levels of serum cytokines and acute phase proteins in patients with essential and cancer-related thrombocytosis. Am J Clin Oncol 2003; 26: 135-40
32. Morceau F, Dicato M, Diederich M. Pro-inflammatory cytokine-mediated anemia: regarding molecular mechanisms of erythropoiesis. Mediators Inflamm 2009; 405016
33. Ikonomi P, Rivera CE, Riordan M, Washington G, Schechter AN, Noguchi CT. Overexpression of GATA-2 inhibits erythroid and promotes megakaryocyte differentiation. E xp Hematol 2000; 28: 1423-31
34. Scosyrev E, Ely BW, Messing EM et al. Do mixed histological features affect survival benefit from neoadjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer? A secondary analysis of Southwest Oncology Group-Directed Intergroup Study (S8710). BJU Int 2011; 108: 693-9
35. Stenzl A, Cowan NC, De Santis M et al. Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Eur Urol 2011; 59: 1009-18
36. Karakiewicz PI, Shariat SF, Palapattu GS et al. Precystectomy nomogram for prediction of advanced bladder cancer stage. Eur Urol 2006; 50: 1254-62
37. Bochner BH, Kattan MW, Vora KC. Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer. J Clin Oncol 2006; 24: 3967-72